CA2462610A1 - Specific binding agents of human angiopoietin-2 - Google Patents

Specific binding agents of human angiopoietin-2 Download PDF

Info

Publication number
CA2462610A1
CA2462610A1 CA002462610A CA2462610A CA2462610A1 CA 2462610 A1 CA2462610 A1 CA 2462610A1 CA 002462610 A CA002462610 A CA 002462610A CA 2462610 A CA2462610 A CA 2462610A CA 2462610 A1 CA2462610 A1 CA 2462610A1
Authority
CA
Canada
Prior art keywords
amino acid
acid residue
seq
polypeptide
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002462610A
Other languages
French (fr)
Other versions
CA2462610C (en
Inventor
Jonathan Daniel Oliner
Hosung Min
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2767061A priority Critical patent/CA2767061C/en
Publication of CA2462610A1 publication Critical patent/CA2462610A1/en
Application granted granted Critical
Publication of CA2462610C publication Critical patent/CA2462610C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.

Claims (117)

1. A polypeptide capable of binding Ang-2 wherein said polypeptide comprises the amino acid sequence WDPWT
(SEQ ID NO: 65) and wherein said polypeptide is from 5 to 50 amino acids in length, and physiologically acceptable salts thereof.
2. A polypeptide capable of binding Ang-2, wherein said polypeptide comprises the amino acid sequence WDPWTC
(SEQ ID NO: 66) and physiologically acceptable salts thereof.
3. A polypeptide capable of binding Ang-2, wherein said polypeptide comprises the amino acid sequence Cz2WDPWT
(SEQ 1D NO: 67) wherein z2 is an acidic or neutral polar amino acid residue, and physiologically acceptable salts thereof.
4. The polypeptide according to claim 3, wherein said polypeptide further comprises the amino acid sequence Cz2WDPWTC
(SEQ ID NO: 68) wherein z2 is an acidic or neutral polar amino acid residue, and physiologically acceptable salts thereof.
5. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:
a1a2a3Ca5WDPWTCa12a13a14 (SEQ ID NO: 69) wherein:
a1l, a2, and a3 are each independently amino acid residues;
a5 is an amino acid residue;
a12 is absent or an amino acid residue;
a13 is absent or a neutral hydrophobic, neutral polar, or a basic amino acid residue;
a14 is a neutral hydrophobic or neutral polar amino acid residue;
and physiologically acceptable salts thereof.
6. The polypeptide according to Claim 5 wherein:
a1 is V, I, P, W, G, S, Q, N, E, K, R, or H;
a2 is V, P, M, G, S, Q, D, E, K, R, or H;
a3 is A, V, P, M, F, T, G, D, E, K, or H;
a8 is A, V, G, Q, N, D, or E;
a12 is S, Q, N, D, E, K, or R;
a13 is L, T, or H;
a14 is V, L, I, W, or M;
and physiologically acceptable salts thereof.
7. The polypeptide according to Claim 5 wherein:
a1 is Q;
a2 is E;
a3 is E;
a5 is D or E;
a12 is D or E;
a13 is H; and a14 is M;
and physiologically acceptable salts thereof.
8. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:
b1b2b3b4b5b6Cb8WDPWTCb15b16b17b18b19b20 (SEQ ID NO: 70) wherein:
b1 is absent or an amino acid residue;
b2 is absent or a neutral hydrophobic, neutral polar, or a basic amino acid residue;
b3, b4, b5, and b6 are each independently absent or amino acid residues;
b8 is an amino acid residue;
b15 is absent or an amino acid residue;
b16 is absent or a neutral hydrophobic, neutral polar, or a basic amino acid residue;
b17 is absent or a neutral hydrophobic or neutral polar amino acid residue;
b18, b19, and b20 are each independently absent or amino acid residues;
and physiologically acceptable salts thereof.
9. The polypeptide according to Claim 8 wherein:
b1 is absent, or A, V, L, P, W, F, T, G, S, Q, N, K, R, or H;
b2 is absent, or A, V, L, I, P, W, M, T, G, S, Y, N, K, R, or H;
b3 is absent, or A, L, I, P, W, M, T, G, S, Q, N, E, R, or H;
b4 is V, I, P, W, G, S, Q, N, E, K, R, or H;
b5 is V, P, M, G, S, Q, D, E, K, R, or H;
b6 is A, V, P, M, F, T, G, D, E, K, or H;
b8 is A, V, G, Q, N, D, or E;
b15 is S, Q, N, D, E, K, or R;
b16 is L, T, or H;
b17 is V, L, I, W, or M;
b18 is absent, or A, V, L, P, W, F, T, G, Y, Q, D, E, or R;
b19 is absent, or V, L, I, P, T, G, S, Y, Q, N, D, E, or R; and b20 is absent, or V, L, P, W, M, T, G, S, Y, Q, N, D, K, or R;

and physiologically acceptable salts thereof.
10. The polypeptide according to Claim 8 wherein:
b1 is absent, or P, or T;
b2 is absent, or I, or N;
b3 is absent, or R, or I;
b4 is Q;
b5 is E;
b6 is E;
b8 is D or E;
b15 is D or E;
b16 is H;
b17 is M;
b18 is absent, or W, or P;
b19 is absent, or G, or E; and b20 is absent, or V, or K.
and physiologically acceptable salts thereof.
11. A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 4, and SEQ ID NO: 76 to SEQ ID
NO: 118, inclusive, wherein said polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof;

PEPTIDE ~SEQ ID NO. ~PEPTIDE SEQUENCE

Con4-44 76 PIRQEECDWDPWTCEHMWEV
Con4-40 77 TNIQEECEWDPWTCDHMPGK
Con4-4 78 WYEQDACEWDPWTCEHMAEV
Con4-31 79 NRLQEVCEWDPWTCEHMENV
Con4-C5 80 AATQEECEWDPWTCEHMPRS
Con4-42 81 LRHQEGCEWDPWTCEHMFDW
Con4-35 82 VPRQKDCEWDPWTCEHMYVG
Con4-43 83 SISHEECEWDPWTCEHMQVG
Con4-49 84 WAAQEECEWDPWTCEHMGRM
Con4-27 85 TWPQDKCEWDPWTCEHMGST
Con4-48 86 GHSQEECGWDPWTCEHMGTS
Con4-46 87 QHWQEECEWDPWTCDHMPSK
Con4-41 88 NVRQEKCEWDPWTCEHMPVR
Con4-36 89 KSGQVECNWDPWTCEHMPRN
Con4-34 90 VKTQEHCDWDPWTCEHMREW
Con4-28 91 AWGQEGCDWDPWTCEHMLPM
Con4-39 92 PVNQEDCEWDPWTCEHMPPM
Con4-25 93 RAPQEDCEWDPWTCAHMDIK
Con4-50 94 HGQNMECEWDPWTCEHMFRY
Con4-38 95 PRLQEECVWDPWTCEHMPLR
Con4-29 96 RTTQEKCEWDPWTCEHMESQ
Con4-47 97 QTSQEDCVWDPWTCDHMVSS
Con4-20 98 QVIGRPCEWDPWTCEHLEGL
Con4-45 99 WAQQEECAWDPWTCDHMVGL
Con4-37 100 LPGQEDCEWDPWTCEHMVRS
Con4-33 101 PMNQVECDWDPWTCEHMPRS
AC2-Con4 102 FGWSHGCEWDPWTCEHMGST
Con4-32 103 KSTQDDCDWDPWTCEHMVGP
Con4-17 104 GPRISTCQWDPWTCEHMDQL
Con4-8 105 STIGDMCEWDPWTCAHMQVD
AC4-Con4 106 VLGGQGCEWDPWTCRLLQGW

Con4-1 107 VLGGQGCQWDPWTCSHLEDG
Con4-C1 108 TTIGSMCEWDPWTCAHMQGG
Con4-21 109 TKGKSVCQWDPWTCSHMQSG
Con4-C2 110 TTIGSMCQWDPWTCAHMQGG
Con4-18 111 WVNEVVCEWDPWTCNHWDTP
Con4-19 112 VVQVGMCQWDPWTCKHMRLQ
Con4-16 113 AVGSQTCEWDPWTCAHLVEV
Con4-11 114 QGMKMFCEWDPWTCAHIVYR
Con4-C4 115 TTIGSMCQWDPWTCEHMQGG
Con4-23 116 TSQRVGCEWDPWTCQHLTYT
Con4-15 117 QWSWPPCEWDPWTCQTVWPS
Con4-9 118 GTSPSFCQWDPWTCSHMVQG
TN8-Con4 4 QEECEWDPWTCEHM
12. A fusion polypeptide comprising at least one peptide according to Claims 1, 5, 8, or 11 and a vehicle, wherein said fusion polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof.
13. The fusion polypeptide according to claim 12 wherein said vehicle is at least one of an Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.
14. The polypeptide according to Claims 1, 5, 8, or 11 which is cyclic.
15. A dimer or multimer of the polypeptides according to Claims 1, 5, 8, or 11.
16. A composition of matter having the formula:
(X1)a-F1-(X2)b and multimers thereof, wherein:
F1 is a vehicle;
X1 and X2 are each independently selected from -(L1)c-P1;
-(L1)c-P1-(L2)d-P2;
-(L1)c-P1-(L2)d-P2-(L3)e-P3; and -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4;
wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide selected from the group consisting of:
(a) the amino acid sequence WDPWT (SEQ ID NO: 65), wherein said polypeptide is from 5 to 50 amino acids in length;
(b) the amino acid sequence WDPWTC (SEQ ID NO: 66), (c) the amino acid sequence Cz2WDPWT (SEQ ID NO: 67), and (d) the amino acid sequence Cz2WDPWTC (SEQ ID NO: 68), wherein z2 is an acidic or neutral polar amino acid residue;
L1, L2, L3, and L4 are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1;
and physiologically acceptable salts thereof.
17. The composition of matter according to claim 16 wherein z2 is A, V, G, Q, N, D, or E.
18. The composition of matter according to claim 16 wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide selected from the group consisting of SEQ ID NO: 4, and SEQ ID NO: 76 to SEQ ID
NO: 118 inclusive.
19. The composition of matter of Claim 16 of the formulae:

or and physiologically acceptable salts thereof.
20. The composition of matter of Claim 16 of the formula:
F1-(L1)c-P1 and physiologically acceptable salts thereof.
21. The composition of matter of Claim 16 of the formula:
F1-(L1)c-P1-(L2)d-P2 and physiologically acceptable salts thereof.
22. The composition of matter of Claim 16 of the formula:
P1-(Li)c-F1-(L2)d-P2 and physiologically acceptable salts thereof.
23. The composition of matter of Claim 16, wherein F1 is an Fc domain or fragment thereof.
24. The composition of matter of Claim 16 wherein F1 comprises the amino acid sequence of SEQ ID NO: 60.
25. A polynucleotide encoding a composition of matter according to Claim 1, 5, 8, or 11.
26. An expression vector comprising the polynucleotide of Claim 25.
27. A host cell comprising the expression vector of Claim 26.
28. The host cell according to Claim 27 wherein the cell is a prokaryotic cell.
29. The host cell according to Claim 28 wherein the cell is an E. coli cell.
30. The host cell according to Claim 27 wherein the cell is a eukaryotic cell.
31. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:
Pc2Dc4Lc6c7c8LY
(SEQ ID NO: 71) wherein c2 is a neutral hydrophobic amino acid residue c4 is a A, D, or E
c6 is an acidic amino acid residue c7 is an amino acid residue; and c8 is a neutral hydrophobic, neutral polar, or basic amino acid residue;
and physiologically acceptable salts thereof.
32. The polypeptide according to claim 31 wherein c2 is L or M.
33. The polypeptide according to claim 31 wherein c6 is D or E.
34. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:
d1d2d3d4Pd6Dd8Ld10d11d12LY d15d16d17d18d19d20d21d22 (SEQ ID NO: 72) wherein, d1 is absent, or an amino acid residue;
d2 is absent, or a neutral polar, acidic, or a basic amino acid residue;
d3 is absent, or a neutral hydrophobic or neutral polar amino acid residue;
d4 is absent, or an amino acid residue;

d6 is a neutral hydrophobic amino acid residue;
d8 is a A, D, or E;
d10 is an acidic amino acid residue;
d11 is an amino acid residue;
d12 is a neutral hydrophobic, neutral polar, or basic amino acid residue;
d15 is absent, or a neutral polar, acidic, or a basic amino acid residue;
d16 is absent, or a neutral polar, acidic, or a basic amino acid residue;
d17 is absent, or a neutral hydrophobic, or neutral polar amino acid residue;
d18 is absent, or a neutral hydrophobic, or neutral polar amino acid residue;
d19 is absent, or a neutral hydrophobic, neutral polar, or basic amino acid residue;
d20 is absent, or an amino acid residue;
d21 is absent, or a neutral polar, acidic, or a basic amino acid residue;
d22 is absent, or a neutral hydrophobic, neutral polar, or basic amino acid residue;
and physiologically acceptable salts thereof.
35. The polypeptide according to Claim 34 wherein:
d1 is T, S, Q, R, or H;
d2 is T, Q, N, or K;
d3 is F;
d4 is M, Q, E, or K;
d6 is L or M;
d8 is D or E;
d10 is E;
d11 is Q or E;
d12 is T or R;
d15 Y, D, E, or K;
d16 is Q;
d17 is W or F;
d18 is L, I, M, or T;

d19 is L, F, or Y;
d20 is Q, D, or E;
d21 is absent, Q, or H;
d22 is absent, A, L, G, S, or R;
and physiologically acceptable salts thereof.
36. A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 6, and SEQ ID NO: 119 to SEQ ID
NO: 142, inclusive, wherein said polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof;

Peptide SEQ ID NO. Peptide Sequence
37. A fusion polypeptide comprising at least one peptide according to Claims 31, 34, or 36 and a vehicle, wherein said fusion polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof.
38. The fusion polypeptide according to Claim 37 wherein said vehicle is at least one of an Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.
39. The polypeptide according to Claim 31, 34, or 36 which is cyclic.
40. A dimer or multimer of the polypeptides according to Claims 31, 34, or 36.
41. A composition of matter having the formula:
(X1)a-F1-(X2)b and multimers thereof, wherein:
F1 is a vehicle;
X1 and X2 are each independently selected from -(L1)c-P1;
-(L1)c-P1-(L2)d-P2;
-(L1)c-P1-(L2)d-P2-(L3)e-P3; and -(L1)c-P1-(L2)d-P2-(L3)e-p3-(L4)f-P4;
wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide according to claim 31, 34, or 36;

L1, L2, L3, and L4 are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1;
and physiologically acceptable salts thereof.
42. The composition of matter of claim 41 wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide selected from the group consisting of SEQ ID NO: 6, and SEQ ID NO: 119 to SEQ ID NO: 142, inclusive.
43. The composition of matter of Claim 41 of the formulae:

or and physiologically acceptable salts thereof.
44. The composition of matter of Claim 41 of the formula:
F1-(L1)c-P1 and physiologically acceptable salts thereof.
45. The composition of matter of Claim 41 of the formula:
F1-(L1)c-P1-(L2)d-P2 and physiologically acceptable salts thereof.
46. The composition of matter of Claim 41 of the formula:
P1-(L1)c-F1-(L2)d-P2 and physiologically acceptable salts thereof.
47. The composition of matter of Claim 41, wherein F1 is an Fc domain or fragment thereof.
48. The composition of matter of Claim 41 wherein F1 comprises the amino acid sequence of SEQ ID NO: 60.
49. A polynucleotide encoding a polypeptide according to any of Claims 31, 34, or 36.
50. An expression vector comprising the polynucleotide of Claim 49.
51. A host cell comprising the expression vector of Claim 50.
52. The host cell according to Claim 51 wherein the cell is a prokaryotic cell.
53. The host cell according to Claim 52 wherein the cell is an E. coli cell.
54. The host cell according to Claim 51 wherein the cell is a eukaryotic cell.
55. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:) RPe3e4e5e6e7G
(SEQ ID NO: 73) wherein e3 is a neutral polar amino acid residue;
e4 is an acidic amino acid residue;
e5 is a neutral polar or an acidic amino acid residue;
e6 is a neutral hydrophobic amino acid residue;
e7 is a neutral hydrophobic amino acid residue;
and physiologically acceptable salts thereof.
56. The polypeptide according to claim 55 wherein e3 is Y or C.
57. The polypeptide according to claim 55 wherein e4 is D or E.
58. The polypeptide according to claim 55 wherein e6 is I or M.
59. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:

f1f2f3f4RPf7f8f9f10f11Gf13f14f15f16f17f18f19f20 (SEQ ID NO: 74) wherein, f1 is a neutral hydrophobic or neutral polar amino acid residue;
f2 is a neutral hydrophobic or neutral polar amino acid residue;
f3 is a neutral polar or acidic amino acid residue;
f4 is a neutral hydrophobic or neutral polar amino acid residue;
f7 is a neutral polar amino acid residue;
f8 is an acidic amino acid residue;
f9 is a neutral polar or acidic amino acid residue;
f10 is a neutral hydrophobic amino acid residue;
f11 is a neutral hydrophobic amino acid residue;
f13 is a neutral hydrophobic or neutral polar amino acid residue;
f14 is a neutral hydrophobic or neutral polar amino acid residue;
f15 is a neutral polar amino acid residue;
f16 is a neutral polar amino acid residue;
f17 is a neutral polar or acidic amino acid residue;
f18 is a neutral hydrophobic or basic amino acid residue;
f19 is a neutral hydrophobic or neutral polar amino acid residue; and f20 is a neutral hydrophobic or neutral polar amino acid residue;
and physiologically acceptable salts thereof.
60. The polypeptide according to Claim 59 wherein:
f1 is S, A, or G;
f2 is G, Q, or P;
f3 is Q, G, or D;

f4 is L, M, or Q;
f7 is C or Y;
f8 is E or D;
f9 is E, G, or D;
f10 is I or M;
f11 is F or L;
f13 is C or W;
f14 is G or P;
f15 T or N;
f16 is Q, Y, or K;
f17 is N, D, or Q;
f18 is L, V, W, or R;
f19 is A, Q, Y, or I; and f20 is L, A, G, or V;
and physiologically acceptable salts thereof.
61. A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 3, and SEQ ID NO: 143 to SEQ ID
NO: 148, inclusive, wherein said polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof;

Peptide SEQ ID NO: Sequence Con1-1 143 AGGMRPYDGMLGWPNYDVQA
Con1-2 144 QTWDDPCMHILGPVTWRRCI
Con1-3 145 APGQRPYDGMLGWPTYQRIV
Con1-4 146 SGQLRPCEEIFGCGTQNLAL
Con1-5 147 FGDKRPLECMFGGPIQLCPR
Con1-6 148 GQDLRPCEDMFGCGTKDWYG
Con1 3 KRPCEEIFGGCTYQ
62. A fusion polypeptide comprising at least one polypeptide according to Claims 55, 59, or 61 and a vehicle, wherein said fusion polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof.
63. The fusion polypeptide according to claim 62 wherein said vehicle is at least one of an Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.
64. The polypeptide according to Claim 55, 59, or 61 which is cyclic.
65. A dimer or multimer of the compounds according to Claims 55, 59, or 61.
66. A composition of matter having the formula:
(X1)a -F1-(X2)b and multimers thereof, wherein:
F1 is a vehicle;
X1 and X2 are each independently selected from -(L1)c-P1 -(L1)c-P1-(L2)d-P2;

-(L1)c-P1-(L2)d -P2-(L3)e -P3; and -(L1)c-P1-(L2)d -P2-(L3)e-P3-(L4)f-P4;
wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide according to Claim 55, 59, or 61;
L1, L2, L3, and L4 are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and bis 1;
and physiologically acceptable salts thereof.
67. The composition of matter of claim 66 wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide selected from the group consisting of SEQ ID NO: 3, and SEQ ID NO: 143 to SEQ ID NO: 148, inclusive.
68. The composition of matter of Claim 66 of the formulae:

or and physiologically acceptable salts thereof.
69. The composition of matter of Claim 66 of the formula:
F1-(L1)c-P1 and physiologically acceptable salts thereof.
70. The composition of matter of Claim 66 of the formula:
F1-(L1)c-P1-(L2)d -P2 and physiologically acceptable salts thereof.
71. The composition of matter of Claim 66 of the formula:
P1-(L1)c-F1-(L2)d-P2 and physiologically acceptable salts thereof.
72. The composition of matter of Claim 66, wherein F1 is an Fc domain or fragment thereof.
73. The composition of matter of Claim 66 wherein F1 comprises the amino acid sequence of SEQ ID NO: 60.
74. A polynucleotide encoding a polypeptide according to any of Claims Claims 55, 59, or 61.
75. An expression vector comprising the polynucleotide of Claim 74.
76. A host cell comprising the expression vector of Claim 75.
77. The host cell according to Claim 76 wherein the cell is a prokaryotic cell.
78. The host cell according to Claim 77 wherein the cell is an E. coli cell.
79. The host cell according to Claim 76 wherein the cell is a eukaryotic cell.
80. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:

Cg2Gg4g5DPFTg10GCg13 (SEQ ID NO: 75) wherein g2 is an acidic amino acid residue;
g4 is a neutral hydrophobic amino acid residue;
g5 is E, D, or Q;
g10 is a neutral hydrophobic or neutral polar amino acid residue;
g13 is an acidic residue;
and physiologically acceptable salts thereof.
81. The polypeptide according to claim 80 wherein g2 is E or D.
82. The polypeptide according to claim 80 wherein g4 is V or M.
83. The polypeptide according to claim 80 wherein g10 is F or Q.
84. The polypeptide according to claim 80 wherein g13 is D or E.
85. A polypeptide capable of binding Ang-2 comprising an amino acid sequence of the formula:

h1h2h3h4Ch6Gh8h9DPFTh14GCh17h18h19h20 (SEQ ID NO: 158) wherein, h1 is absent or a neutral hydrophobic, neutral polar, or a basic amino acid residue;
h2 is a neutral hydrophobic or neutral polar amino acid residue;
h3 is an acidic amino acid residue;
h4 is a neutral hydrophobic or neutral polar amino acid residue;
h6 is an acidic amino acid residue;
h8 is a neutral hydrophobic amino acid residue;
h9 is E, D, or Q;
h14 is a neutral hydrophobic or neutral polar amino acid residue;
h17 is an acidic amino acid residue;
h18 is a neutral hydrophobic, neutral polar, or a basic amino acid residue;
h19 is a neutral hydrophobic or neutral polar amino acid residue; and h20 is absent or an amino acid residue;
and physiologically acceptable salts thereof.
86. The polypeptide according to Claim 85 wherein:
h1 is absent, or A, L, M, G, K, or H;

h2 is L, F, or Q;
h3 is D or E;
h4 is W or Y;
h6 is D or E;
h8 is V or M;
h14 is F or Q;
h17 is D or E;
h18 is M, Y, N, or K;
h19 is L or Q; and h20 is absent or M, T, G, S, D, K, or R;
and physiologically acceptable salts thereof.
87. A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 5, and SEQ ID NO: 149 to SEQ ID
NO: 157, inclusive, wherein said polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof;

Peptide SEQ ID NO: Sequence
88. A fusion polypeptide comprising at least one peptide according to Claim 80, 85, or 87, and a vehicle, wherein said fusion polypeptide is capable of binding to Ang-2, and physiologically acceptable salts thereof.
89. The fusion polypeptide according to Claim 88 wherein said vehicle is at least one of an Fc domain, polyethylene glycol, a lipid, a cholesterol group, a carbohydrate, and an oligosaccharide.
90. The polypeptide according to Claim 80, 85, or 87 which is cyclic.
91. A dimer or multimer of the polypeptides according to Claims 80, 85, or 87.
92. A composition of matter having the formula:

(X1)a -F1-(X2)b and multimers thereof, wherein:
F1 is a vehicle;
X1 and X2 are each independently selected from -(L1)c -P1;
-(L1)c -P1-(L2)d-P2;
-(L1)c -P1-(L2)d-P2-(L3)e -P3; and -(L1)c -P1-(L2)d-P2-(L3)e P3-(L4)F -p4;
wherein one or more of P1, p2, p3, and P4 each independently comprise a polypeptide according to Claim 80, 85, or 87;
L1, L2, L3, and L4 are each independently linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1;
and physiologically acceptable salts thereof.
93. The composition of matter of claim 92 wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide selected from the group consisting of SEQ ID NO: 5, and SEQ ID NO: 149 to SEQ ID NO: 157, inclusive.
94. The composition of matter of Claim 92 of the formulae:

or and physiologically acceptable salts thereof.
95. The composition of matter of Claim 92 of the formula:

F1-(L1)c -P1 and physiologically acceptable salts thereof.
96. The composition of matter of Claim 92 of the formula:

F1-(L1)c-P1-(L2)d-P2 and physiologically acceptable salts thereof.
97. The composition of matter of Claim 92 of the formula:

P1-(L1)c-F1-(L2)d-P2 and physiologically acceptable salts thereof.
98. The composition of matter of Claim 92, wherein F1 is an Fc domain or fragment thereof.
99. The composition of matter of Claim 92 wherein F1 comprises the amino acid sequence of SEQ ID NO: 60.
100. A polynucleotide encoding a polypeptide according to any of Claims 80, 85, or 87.
101. An expression vector comprising the polynucleotide of Claim 100.
102. A host cell comprising the expression vector of Claim 101.
103. The host cell according to Claim 102 wherein the cell is a prokaryotic cell.
104. The host cell according to Claim 103 wherein the cell is an E. coli cell.
105. The host cell according to Claim 102 wherein the cell is a eukaryotic cell.
106. A polypeptide according to any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID
NO: 3, or SEQ ID NO: 4, or a variant thereof.
107. A polypeptide according to any of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ
ID NO: 7, or a variant thereof.
108. A composition of matter having the formula:

(X1)q-F1-(X2)r and multimers thereof, wherein:
F1 is a vehicle;
X1 and X2 are each independently selected from -(L1)s-P1;
-(L1)s-P1-(L2)t-P2;
-(L1)s -P1-(L2)t-P2-(L3)u-P3; and -(L1)s-P1-(L2)t-P2-(L3)u-P3-(L4)v-P4;
wherein one or more of P1, P2, P3, and P4 each independently comprise a polypeptide selected from the group consisting of:
(a) the amino acid sequence WDPWT (SEQ ID NO: 65), wherein said polypeptide is from 5 to 50 amino acids in length;
(b) the amino acid sequence WDPWTC (SEQ ID NO: 66);

(c) the amino acid sequence Cz2WDPWT (SEQ ID NO: 67), wherein z2 is an acidic or neutral polar amino acid residue;
(d) the amino acid sequence Cz2WDPWTC (SEQ ID NO: 68), wherein z2 is an acidic or neutral polar amino acid residue;
(e) the amino acid sequence Pc2Dc4Lc6c7c8LY (SEQ ID NO: 71) wherein c2 is a neutral hydrophobic amino acid residue; c4 is a A, D, or E; c6 is an acidic amino acid residue; c7 is an amino acid residue; and c8 is a neutral hydrophobic, neutral polar, or basic amino acid residue;
(f) the amino acid sequence RPe3e4e5e6e7G (SEQ ID NO: 73) wherein e3 is a neutral polar amino acid residue; e4 is an acidic amino acid residue; e5 is a neutral polar or an acidic amino acid residue; e6 is a neutral hydrophobic amino acid residue; and e7 is a neutral hydrophobic amino acid residue;
(g) the amino acid sequence Cg2Gg4g5DPFTg10GCg13 (SEQ ID NO: 75) wherein g2 is an acidic amino acid residue; g4 is a neutral hydrophobic amino acid residue; g5 is a neutral polar or an acidic amino acid residue;
g10 is a neutral hydrophobic or neutral polar amino acid residue; and g13 is an acidic residue;
(h) A polypeptide of SEQ ID NO: 1;
(i) A polypeptide of SEQ ID NO: 2; and (j) A polypeptide of SEQ ID NO: 7;
L1, L2, L3, and L4 are each independently linkers; and q, r, s, t, u, and v are each independently 0 or 1, provided that at least one of q and r is 1;
and physiologically acceptable salts thereof.
109. A pharmaceutical composition comprising an effective amount of a composition according to Claims 1, 31, 55, or 80 in admixture with a pharmaceutically acceptable carrier thereof.~
110. A method of inhibiting undesired angiogenesis in a mammal comprising administering a therapeutically effective amount of the composition according to Claim 12, 16, 37, 41, 62, 66, 88, or 92.
111. A method of treating angiogenesis in a subject, said method comprising administering an effective amount of a composition of Claim 12, 16, 37, 41, 62, 66, 88, or 92.
112. A method of modulating angiogenesis in a mammal comprising administering a therapeutically effective amount of the composition according to Claim 12, 16, 37, 41, 62, 66, 88, or 92.
113. A method of inhibiting tumor growth characterized by undesired angiogenesis in a mammal comprising administering a therapeutically effective amount of the composition according to Claim 12, 16, 37, 41, 62, 66, 88, or 92.
114. A method of treating cancer in a mammal comprising administering a therapeutically effective amount of the composition according to Claim 12, 16, 37, 41, 62, 66, 88, or 92 and a chemotherapeutic agent.
115. The method according to claim 114 wherein the chemotherapeutic agent is at least one of 5-FU, CPT-11, and Taxotere.
116. A method of modulating at least one of vascular permeability or plasma leakage in a mammal comprising administering a therapeutically effective amount of the composition according to Claim 12, 16, 37, 41, 62, 66, 88, or 92.
117. A method of treating at least one of ocular neovascular disease, obesity, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, inflammatory disorders, atherosclerosis, endometriosis, neoplastic disease, bone-related disease, or psoriasis in a mammal comprising administering a therapeutically effective amount of the composition according to Claim 12, 16, 37, 41, 62, 66, 88, or 92.
CA2462610A 2001-10-11 2002-10-11 Specific binding agents of human angiopoietin-2 Expired - Lifetime CA2462610C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2767061A CA2767061C (en) 2001-10-11 2002-10-11 Specific binding agents of human angiopoietin-2

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32862401P 2001-10-11 2001-10-11
US60/328,624 2001-10-11
US41415502P 2002-09-27 2002-09-27
US60/414,155 2002-09-27
US10/269,695 2002-10-10
US10/269,695 US7138370B2 (en) 2001-10-11 2002-10-10 Specific binding agents of human angiopoietin-2
PCT/US2002/032657 WO2003057134A2 (en) 2001-10-11 2002-10-11 Specific binding agents of human angiopoietin-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2767061A Division CA2767061C (en) 2001-10-11 2002-10-11 Specific binding agents of human angiopoietin-2

Publications (2)

Publication Number Publication Date
CA2462610A1 true CA2462610A1 (en) 2003-07-17
CA2462610C CA2462610C (en) 2012-09-18

Family

ID=27402210

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2767061A Expired - Lifetime CA2767061C (en) 2001-10-11 2002-10-11 Specific binding agents of human angiopoietin-2
CA2462610A Expired - Lifetime CA2462610C (en) 2001-10-11 2002-10-11 Specific binding agents of human angiopoietin-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2767061A Expired - Lifetime CA2767061C (en) 2001-10-11 2002-10-11 Specific binding agents of human angiopoietin-2

Country Status (26)

Country Link
US (7) US7138370B2 (en)
EP (5) EP2070944B1 (en)
JP (3) JP4573238B2 (en)
KR (2) KR20100038238A (en)
CN (3) CN101812118A (en)
AT (1) ATE444967T1 (en)
AU (2) AU2002365179B2 (en)
BR (1) BRPI0213223B8 (en)
CA (2) CA2767061C (en)
CY (1) CY1110571T1 (en)
DE (1) DE60233955D1 (en)
DK (1) DK1434791T3 (en)
EA (1) EA008248B1 (en)
ES (3) ES2334118T3 (en)
HK (3) HK1076113A1 (en)
HU (1) HUP0402162A3 (en)
IL (2) IL161016A0 (en)
ME (2) ME00185B (en)
MX (1) MXPA04003342A (en)
NO (1) NO336004B1 (en)
NZ (4) NZ554022A (en)
PL (1) PL224701B1 (en)
PT (1) PT1434791E (en)
RS (1) RS51898B (en)
SI (1) SI1434791T1 (en)
WO (1) WO2003057134A2 (en)

Families Citing this family (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934425T2 (en) 1998-10-23 2007-09-27 Amgen Inc., Thousand Oaks THROMBOPOIETIN SUBSTITUTE
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
TW201319088A (en) 2003-07-18 2013-05-16 Amgen Inc Specific binding agents to hepatocyte growth factor
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
KR20050047030A (en) 2003-11-13 2005-05-19 한미약품 주식회사 Igg fc fragment for a drug carrier and method for the preparation thereof
US20060080092A1 (en) * 2004-07-28 2006-04-13 Sherman Edward S Telecommunication device and method
DK1797127T3 (en) * 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
JP2008543839A (en) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド Self-buffering protein formulation
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SI2500360T1 (en) * 2005-10-31 2015-11-30 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CA2633211A1 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
AR059066A1 (en) * 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
US20070179094A1 (en) * 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
US7873029B2 (en) 2006-03-06 2011-01-18 At&T Intellectual Property I, L.P. System and method of providing multimedia communication services
JO3324B1 (en) 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
AU2007318912B2 (en) * 2006-11-10 2011-03-03 Covx Technologies Ireland Limited Anti-angiogenic compounds
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
SG10201500328QA (en) 2007-08-21 2015-03-30 Amgen Inc Human c-fms antigen binding proteins
MX2010002249A (en) * 2007-08-31 2010-03-17 Amgen Inc Solid-state protein formulation.
WO2009043049A2 (en) * 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EP2769991B1 (en) 2008-01-03 2018-08-22 The Scripps Research Institute Antibody targeting through a modular recognition domain
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN103002911B (en) 2008-09-26 2015-08-26 昂考梅德药品有限公司 FZ is in conjunction with medicament and application thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2445923B1 (en) * 2009-06-22 2018-09-05 Amgen, Inc Refolding proteins using a chemically controlled redox state
TWI513465B (en) 2009-06-25 2015-12-21 Regeneron Pharma Method of treating cancer with dll4 antagonist and chemotherapeutic agent
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
RU2573915C2 (en) 2009-09-16 2016-01-27 Дженентек, Инк. Protein complexes containing superhelix and/or banding, and their use
US20120183546A1 (en) * 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
JO3183B1 (en) 2010-01-29 2018-03-08 Regeneron Pharma Methods of treating autoimmune diseases with dll4 antagonists
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
CN102971337B (en) 2010-04-01 2016-09-21 昂考梅德药品有限公司 FZ combines medicament and application thereof
MX346731B (en) 2010-04-23 2017-03-30 Genentech Inc * Production of heteromultimeric proteins.
WO2011156373A1 (en) 2010-06-07 2011-12-15 Amgen Inc. Drug delivery device
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EA201370076A1 (en) 2010-09-22 2013-08-30 Амген Инк. IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2018108836A (en) 2011-02-04 2019-03-14 Дженентек, Инк. Fc OPTIONS AND METHODS FOR PRODUCING THEM
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
KR101638224B1 (en) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 Antigen binding proteins
JP5768147B2 (en) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Monovalent antigen binding protein
MX341790B (en) 2011-03-31 2016-09-02 Amgen Inc Vial adapter and system.
PT2699293T (en) 2011-04-20 2019-05-21 Amgen Inc Autoinjector apparatus
ES2704038T3 (en) 2011-05-24 2019-03-13 Zyngenia Inc Multivalent and monovalent multispecific complexes and their uses
MX358726B (en) 2011-06-29 2018-09-03 Amgen Inc Predictive biomarker of survival in the treatment of renal cell carcinoma.
EP3348575A1 (en) 2011-08-16 2018-07-18 Emory University Jaml specific binding agents, antibodies, and uses related thereto
CN107266577B (en) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 Improved assembly of bispecific antibodies
IL308846A (en) 2011-10-14 2024-01-01 Amgen Inc Injector and method of assembly
WO2013063298A1 (en) 2011-10-26 2013-05-02 Amgen Inc. Methods of reducing or eliminating protein modification and degradation arising from exposure to uv light
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
BR112014017882A2 (en) * 2012-01-23 2017-06-27 Regeneron Pharma stabilized formulations containing anti-ang-2 antibodies
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
BR112014032193A2 (en) 2012-06-27 2017-06-27 Hoffmann La Roche bispecific antibody production and combination determination methods, bispecific antibody, formulation and use of bispecific antibody
HRP20211641T1 (en) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
MX2015002985A (en) * 2012-09-07 2015-06-22 Sanofi Sa Fusion proteins for treating a metabolic syndrome.
KR101967345B1 (en) 2012-10-18 2019-04-09 삼성전자주식회사 Peptides for inhibition of binding between angiopoietin-2 and integrin and uses thereof
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
AR093445A1 (en) 2012-11-14 2015-06-10 Regeneron Pharma METHODS TO TREAT OVARY CANCER WITH DLL4 ANTAGONISTS
AU2013348071B2 (en) 2012-11-21 2018-05-24 Amgen Inc. Drug delivery device
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI580452B (en) 2013-03-15 2017-05-01 安美基公司 Cassette for an injector, injector, and method of using an apparatus comprising an autoinjector and a cassette
WO2014144096A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX
ES2853748T3 (en) 2013-03-22 2021-09-17 Amgen Inc Injector and mounting method
KR102131371B1 (en) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 specific antibodies and uses thereof
EP3381940B1 (en) 2013-07-29 2022-09-07 Samsung Electronics Co., Ltd. Anti-ang2 antibody
KR102196450B1 (en) 2013-09-17 2020-12-30 삼성전자주식회사 Anticancer composition containing an anti-Ang2 antibody inducing binding to Tie2 receptor
MX2016003593A (en) 2013-10-11 2016-06-02 Hoffmann La Roche Multispecific domain exchanged common variable light chain antibodies.
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
ES2744837T3 (en) 2013-10-24 2020-02-26 Amgen Inc Injector and assembly procedure
WO2015090234A1 (en) * 2013-12-19 2015-06-25 Beijing Anxinhuaide Biotech. Co., Ltd Improving pharmacokinetic profile for angiopoietin-2 inhibiting polypeptide or thymalfasin
KR102206029B1 (en) 2014-01-27 2021-01-20 삼성전자주식회사 Antibody specifically binding to Ang-2 and use thereof
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
KR20230164192A (en) 2014-05-06 2023-12-01 제넨테크, 인크. Production of heteromultimeric proteins using mammalian cells
KR102496507B1 (en) 2014-05-07 2023-02-03 암겐 인코포레이티드 Autoinjector with shock reducing elements
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
IL297356A (en) 2014-06-03 2022-12-01 Amgen Inc Controllable drug delivery system and method of use
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
ES2785311T3 (en) 2014-12-19 2020-10-06 Amgen Inc Mobile button drug delivery device or user interface field
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2016176427A1 (en) 2015-04-30 2016-11-03 Amgen Inc. Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
US11098079B2 (en) 2015-08-13 2021-08-24 Amgen Inc. Charged depth filtration of antigen-binding proteins
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
DK3430031T3 (en) * 2016-03-15 2022-01-17 Idp Discovery Pharma S L PEPTIDS WITH ANTI-CANCER ACTIVITY
ES2814287T3 (en) 2016-03-15 2021-03-26 Amgen Inc Reduce the likelihood of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
CN109310756B (en) * 2016-05-13 2022-06-28 奥美药业有限公司 Novel angiopoietin 2, VEGF bispecific antagonists
CA3018426A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
US11059885B2 (en) * 2016-05-13 2021-07-13 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN109071656B (en) 2017-01-05 2021-05-18 璟尚生物制药公司 Checkpoint modulator antagonists
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for drug delivery device
FI3600491T3 (en) 2017-03-28 2023-10-20 Amgen Inc Plunger rod and syringe assembly system and method
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019015472A (en) 2017-06-22 2020-02-19 Amgen Inc Device activation impact/shock reduction.
MA49461A (en) 2017-06-23 2020-04-29 Amgen Inc ELECTRONIC DRUG DELIVERY DEVICE INCLUDING A CAP ACTIVATED BY A SWITCH ASSEMBLY
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
JP2020527376A (en) 2017-07-21 2020-09-10 アムジエン・インコーポレーテツド Gas permeable sealing material and assembly method for drug containers
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49676A (en) 2017-07-25 2020-06-03 Amgen Inc DRUG ADMINISTRATION DEVICE EQUIPPED WITH A CONTAINER ACCESS SYSTEM AND ASSOCIATED ASSEMBLY PROCEDURE
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (en) 2017-10-09 2020-08-19 Amgen Inc DRUG ADMINISTRATION DEVICE INCLUDING A TRAINING ASSEMBLY AND ASSOCIATED ASSEMBLY PROCEDURE
MA50528A (en) 2017-11-03 2020-09-09 Amgen Inc SYSTEMS AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (en) 2017-11-06 2020-09-16 Amgen Inc FILLING-FINISHING UNITS AND ASSOCIATED PROCESSES
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
MA50903A (en) 2017-11-16 2021-05-12 Amgen Inc SELF-INJECTOR WITH STALL AND END POINT DETECTION
CN111278487B (en) 2017-11-16 2022-06-24 安进公司 Door latch mechanism for a drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3813880A4 (en) 2018-06-29 2022-07-13 Gensun Biopharma Inc. Antitumor immune checkpoint regulator antagonists
CN112351804A (en) 2018-07-24 2021-02-09 安进公司 Delivery device for administering a drug
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US20210228815A1 (en) 2018-07-24 2021-07-29 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
AU2019350660A1 (en) 2018-09-28 2021-03-18 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
EA202191037A1 (en) 2018-10-15 2021-08-05 Эмджен Инк. A DRUG DELIVERY DEVICE WITH A DAMPER MECHANISM
CN112689523A (en) 2018-10-15 2021-04-20 安进公司 Platform assembly method for drug delivery device
BR112021007611A2 (en) 2018-10-23 2021-07-27 Amgen Inc. automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US20220031953A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial needle retraction
MA54057A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY ELEMENT PARTIAL RETRACTION DRUG DELIVERY DEVICES
JP2022529319A (en) 2019-04-24 2022-06-21 アムジエン・インコーポレーテツド Syringe sterility confirmation assembly and method
KR102400401B1 (en) * 2019-05-22 2022-05-24 (주)셀인바이오 Anti-inflammatory peptide and anti-inflammatory composition
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
KR102195957B1 (en) * 2019-11-19 2020-12-28 삼성전자주식회사 Anti-Ang2 antibody inducing binding to Tie2 receptor
KR102312922B1 (en) * 2019-11-19 2021-10-13 삼성전자주식회사 Anti-Ang2 antibody inducing binding to Tie2 receptor
WO2021158469A1 (en) 2020-02-03 2021-08-12 Amgen Inc. Multivariate bracketing approach for sterile filter validation
CN115996946A (en) 2020-04-30 2023-04-21 免疫靶向有限公司 Activatable IL2 compositions and methods of use
CN112126671B (en) * 2020-08-18 2021-08-31 中山大学附属第五医院 Application of streptococcus agalactiae streptococcus agalactiae in treating endometriosis
CN116209765A (en) * 2020-08-19 2023-06-02 药物抗体公司 Modified antibodies and methods of making the same
AU2022238389A1 (en) * 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2022256820A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
AR127458A1 (en) 2021-10-27 2024-01-24 Amgen Inc PREDICTION BASED ON DEEP LEARNING USING SPECTROSCOPY
WO2023173084A1 (en) 2022-03-11 2023-09-14 University Of Rochester Cyclopeptibodies and uses thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DE3889853D1 (en) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharide-modified immunoglobulins with reduced immunogenic potential or improved pharmacokinetics.
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
DE69332197T2 (en) 1992-03-13 2003-04-17 Organon Teknika Bv Epstein-Barr virus related peptides and nucleic acid segments
DE69312700T2 (en) 1992-04-14 1998-02-19 Cornell Res Foundation Inc MACROMOLECULES BASED ON DENDRITIC POLYMERS AND METHOD FOR THE PRODUCTION THEREOF
ATE311895T1 (en) 1992-05-26 2005-12-15 Immunex Corp NEW CYTOKINE THAT BINDS CD30
WO1994000469A1 (en) * 1992-06-26 1994-01-06 Immunex Corporation Novel tyrosine kinase
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
WO1995013387A1 (en) 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tie-2, a novel receptor tyrosine kinase
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) * 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
EP0742830B1 (en) 1994-02-01 2001-07-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Fusion proteins that include antibody and nonantibody portions
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2000077037A2 (en) 1999-06-15 2000-12-21 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5854202A (en) 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
JP4122056B2 (en) * 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド TIE-2 ligand, methods for making and using the same
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5670110A (en) 1995-12-21 1997-09-23 The Procter & Gamble Company Method for making three-dimensional macroscopically-expanded webs having improved functional surfaces
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
JP2001512560A (en) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ Methods and means for the selection of peptides and proteins with specific affinity for a target
IL130908A0 (en) 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
AU6542898A (en) 1997-03-05 1998-09-22 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6077934A (en) 1997-12-24 2000-06-20 University Of Utah Research Foundation Contryphan peptides
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
CA2368670C (en) 1999-03-26 2012-06-05 Chitra Suri Modulation of vascular permeability by means of tie2 receptor activators
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
DK1187918T4 (en) 1999-06-07 2009-02-23 Immunex Corp Tek antagonists
AU2001245308A1 (en) 2000-02-24 2001-09-03 Human Genome Sciences, Inc. 207 human secreted proteins
AU2001238347A1 (en) * 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001245945A1 (en) 2000-03-23 2001-10-03 Pe Corporation (Ny) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
EP1160321A1 (en) 2000-05-31 2001-12-05 Sanofi-Synthelabo Kidney Injury Novel Gene-1: Isolation and therapeutic applications
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2013180295A1 (en) 2012-06-01 2013-12-05 日本電信電話株式会社 Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
EP3035305B1 (en) 2014-12-18 2016-11-16 Axis AB Enclosure and arrangement for recess mounting of a camera or camera head

Also Published As

Publication number Publication date
JP2009273457A (en) 2009-11-26
DK1434791T3 (en) 2010-02-15
KR20100038238A (en) 2010-04-13
JP4573238B2 (en) 2010-11-04
JP2005514024A (en) 2005-05-19
EP2316845A1 (en) 2011-05-04
US9200040B2 (en) 2015-12-01
AU2009202513C1 (en) 2010-03-11
US20090054323A1 (en) 2009-02-26
CN101787072A (en) 2010-07-28
US7723499B2 (en) 2010-05-25
IL161016A (en) 2014-07-31
RS51898B (en) 2012-02-29
US20130158234A1 (en) 2013-06-20
NO336004B1 (en) 2015-04-20
NZ543687A (en) 2008-04-30
EP1434791B1 (en) 2009-10-07
PL372671A1 (en) 2005-07-25
EP2311849B1 (en) 2017-08-16
US20140275479A1 (en) 2014-09-18
EA008248B1 (en) 2007-04-27
HK1145692A1 (en) 2011-04-29
HUP0402162A3 (en) 2009-03-30
CA2462610C (en) 2012-09-18
EP2157097A1 (en) 2010-02-24
CN101812118A (en) 2010-08-25
ES2334118T3 (en) 2010-03-05
MXPA04003342A (en) 2004-07-08
EP1434791A2 (en) 2004-07-07
EA200400526A1 (en) 2005-06-30
MEP32008A (en) 2010-10-10
US20030229023A1 (en) 2003-12-11
CN1596266A (en) 2005-03-16
AU2009202513A1 (en) 2009-07-16
CA2767061C (en) 2014-03-18
CN101787072B (en) 2015-07-15
US20100286060A1 (en) 2010-11-11
EP2311849A1 (en) 2011-04-20
DE60233955D1 (en) 2009-11-19
JP5432777B2 (en) 2014-03-05
PT1434791E (en) 2009-12-30
EP2316845B1 (en) 2013-01-16
AU2002365179B2 (en) 2006-02-23
JP2010189394A (en) 2010-09-02
YU37304A (en) 2006-08-17
US8129331B2 (en) 2012-03-06
SI1434791T1 (en) 2010-01-29
WO2003057134A8 (en) 2004-08-19
HK1133017A1 (en) 2010-03-12
HK1076113A1 (en) 2006-01-06
NO20041917D0 (en) 2004-05-10
IL161016A0 (en) 2004-08-31
NZ554021A (en) 2009-02-28
KR100976915B1 (en) 2010-08-18
ME00185B (en) 2010-10-10
EP2070944A1 (en) 2009-06-17
NO20041917L (en) 2004-07-08
HUP0402162A2 (en) 2005-01-28
US20060122370A1 (en) 2006-06-08
NZ554023A (en) 2009-02-28
CA2767061A1 (en) 2003-07-17
EP2070944B1 (en) 2012-09-26
BRPI0213223B1 (en) 2019-05-21
CY1110571T1 (en) 2015-04-29
WO2003057134A2 (en) 2003-07-17
PL224701B1 (en) 2017-01-31
US7138370B2 (en) 2006-11-21
ES2396272T3 (en) 2013-02-20
KR20040068119A (en) 2004-07-30
AU2009202513B2 (en) 2009-08-27
CN1596266B (en) 2010-04-28
EP1434791A4 (en) 2006-04-26
WO2003057134A3 (en) 2004-04-29
NZ554022A (en) 2010-01-29
BR0213223A (en) 2005-04-26
AU2002365179A1 (en) 2003-07-24
ES2402918T3 (en) 2013-05-10
US20120141499A1 (en) 2012-06-07
ATE444967T1 (en) 2009-10-15
BRPI0213223B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
CA2462610A1 (en) Specific binding agents of human angiopoietin-2
CA2522248A1 (en) Methods of treatment using specific binding agents of human angiopoietin-2
Brisson et al. Structure of soluble and membrane-bound human annexin V
CA2446189A1 (en) Peptides and related molecules that bind to tall-1
RU2219941C2 (en) Agonists of apolipoprotein a-1 and their application for treatment of dyslipidemia-associated diseases
Aileen Funke et al. Peptides for therapy and diagnosis of Alzheimer's disease
Takahashi Conformation of membrane fusion-active 20-residue peptides with or without lipid bilayers. Implication of. alpha.-helix formation for membrane fusion
DE69837809T2 (en) APOLIPOPROTEIN A-I AGONISTS AND THEIR USE FOR THE TREATMENT OF DISLIPIDEMIC ILLNESSES
CN103443123B (en) Lipoprotein complexes and their preparation and use
HRP20210809T1 (en) Bicyclic peptide ligands specific for mt1-mmp
JP7095037B2 (en) Higher effectiveness for removing apoE mimetic peptides and plasma cholesterol
JP4903717B2 (en) Tripeptide and tetrapeptide sulfone
Fletcher et al. De novo coiled-coil peptides as scaffolds for disrupting protein–protein interactions
US20030039654A1 (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
JP2001518282A (en) Apolipoprotein A-1 agonists and their use for treating dyslipidemic disorders
CA2473032A1 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
ES2393373T3 (en) Method for the production of insulin-like growth factor-I
JP2011256192A5 (en) COMPOSITION CONTAINING IMPROVED APO E
CN101522711B (en) Reconstituted surfactants having improved properties
JP2002503641A5 (en)
CA3089279A1 (en) Cell-permeable stapled peptide modules for cellular delivery
CA2730132A1 (en) Novel angiopoietin derived peptides
US20200140481A1 (en) Preparation of biologically active complexes
MXPA02010324A (en) Apo ai aii peptide derivatives.
Rocha et al. Design and biological activity of β-sheet breaker peptide conjugates

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20221011